1402924-31-5

1402924-31-5 structure

Name: Valganciclovir-d5 TFA
Chemical Name: Valganciclovir-d5 TFA
CAS Number: 1402924-31-5
Molecular Formula: C₁₆H₁₈D₅F₃N₆O₇
Molecular Weight: 473.42
Catalog: Signaling Pathways Anti-infection CMV
Create Date: 2023-04-21 11:19:37
Modify Date: 2024-01-31 17:42:55
Valganciclovir-d5 (TFA) is the deuterium labeled Valganciclovir TFA[1]. Valganciclovir, the L-valyl ester of ganciclovir, is actually a prodrug for ganciclovir. Valganciclovir is an antiviral medication used to treat cytomegalovirus infections[2][3][4].

Name	Valganciclovir-d5 TFA

Description	Valganciclovir-d5 (TFA) is the deuterium labeled Valganciclovir TFA[1]. Valganciclovir, the L-valyl ester of ganciclovir, is actually a prodrug for ganciclovir. Valganciclovir is an antiviral medication used to treat cytomegalovirus infections[2][3][4].
Related Catalog	Signaling Pathways >> Anti-infection >> CMV
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9. [3]. Chawla JS, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun14(3):259-67. [4]. O'Brien S, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15111(4):1816-9.

Molecular Formula	C₁₆H₁₈D₅F₃N₆O₇
Molecular Weight	473.42